Clinical Trials List
2015-12-01 - 2026-12-31
Phase II
Recruiting5
ICD-10C00.0
Malignant neoplasm of external upper lip
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9140.0
Malignant neoplasm of upper lip, vermilion border
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Po-Jung Su Division of Hematology & Oncology
- Wen-Chi Chou Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- Wen-Chi Shen Division of Hematology & Oncology
- 吳教恩 Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- 余紹銘 Division of Hematology & Oncology
- Ming-Mo Hou Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chien-Chung Lin Division of General Internal Medicine
- Wu-Chou Su Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- Po-Lan Su Division of General Internal Medicine
- Yu-Min Yeh Division of Hematology & Oncology
- Wen-Pin Su Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Jih-Hsiang Lee Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
1595 participants
